Clinical effects of tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine in the treatment of AVMC and its effects on serum TNF‑α, IL‑18 and IL‑35
- Authors:
- Published online on: August 31, 2018 https://doi.org/10.3892/etm.2018.6671
- Pages: 4070-4074
-
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Clinical effects of tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine in the treatment of acute viral myocarditis (AVMC) were investigated. Eighty‑six patients with AVMC treated in Dongying City People's Hospital from August 2016 to July 2017 were selected and randomly divided into control group (n=43) and observation group (n=43). Patients in control group were treated with tanshinone ⅡA sodium sulfonate, while those in observation group were treated with trimetazidine and levocarnitine. The curative effect and improvement in clinical symptoms were compared between the two groups of patients, and enzyme‑linked immunosorbent assay (ELISA) was used to detect the levels of heart‑type fatty acid‑binding protein (H‑FABP), creatine kinase‑MB (CK‑MB) and cardiac troponin I (cTnI) in patients after treatment. Besides, the changes in levels of serum tumor necrosis factor‑α (TNF‑α), interleukin (IL)‑18 and IL‑35 were detected via ELISA. The total effective rate of treatment in observation group was significantly higher than that in control group (p<0.05). The improvement in clinical symptoms in observation group was significantly superior to that in control group (p<0.05). After treatment, levels of H‑FABP, CK‑MB and cTnI in observation group were obviously lower than those in control group (p<0.05). At 3, 5 and 7 days after treatment, the levels of TNF‑α and IL‑18 in both groups of patients were decreased compared with those before treatment, but the level of IL‑35 was increased compared with that before treatment, and changes in observation group were more significant than those in control group (p<0.05). Tanshinone ⅡA sodium sulfonate combined with trimetazidine and levocarnitine has definite curative effects in the treatment of patients with AVMC, which can alleviate myocardial injury with higher safety, and effectively mitigate the inflammatory response in patients, so it is of great clinical significance.
